Anticonvulsant evaluation of novel non-imidazole histamine H3R antagonists in different convulsion models in rats

Alaa Alachkar, Gniewomir Latacz, Agata Siwek, Annamaria Lubelska, Ewelina Honkisz, Anna Gryboś, Dorota Łażewska, Jadwiga Handzlik, Holger Stark, Katarzyna Kiec-Kononowicz, Bassem Sadek

Research output: Contribution to journalArticlepeer-review

9 Citations (Scopus)


Novel non-imidazole histamine H3 receptor (H3R) antagonists (2–8) were developed and assessed for in-vitro antagonist binding affinities at the human histamine H1–H4R. These novel H3R antagonists (2–8) were examined in-vivo for anticonvulsant effects in three different convulsion models in male adult rats. Compound 6 significantly and dose-dependently exhibited decreased duration of tonic hind limb extension (THLE) in the maximal electroshock (MES)- and fully protected animals against pentylenetetrazole (PTZ)-induced convulsion, following acute systemic administration (5, 10, and 20 mg/kg, i.p.). Contrary, all compounds 2–8 showed moderate protection in the strychnine (STR)-induced convulsion model following acute pretreatment (10 mg/kg, i.p.). Moreover, the acute systemic administration of H3R antagonist 6 (10 mg/kg, i.p.) significantly prolonged latency time for MES convulsions. Furthermore, the anticonvulsant effect observed with compound 6 in MES-model was entirely abrogated when rats were co-injected with the brain penetrant H1R antagonist pyrilamine (PYR) but not the brain penetrant H2R antagonist zolantidine (ZOL). However, PYR and ZOL failed to abolish the full protection provided by the H3R antagonist 6 in PTZ- and STR-models. No mutagenic or antiproliferative effects or potential metabolic interactions were shown for compound 6 when assessing its antiproliferative activities and metabolic profiling applying in-vitro methods. These findings demonstrate the potential of non-imidazole H3R antagonists as novel antiepileptic drugs (AEDs) either for single use or in addition to currently available epilepsy medications.

Original languageEnglish
Pages (from-to)14-24
Number of pages11
JournalPharmacology Biochemistry and Behavior
Publication statusPublished - Jul 2018


  • Antagonists
  • Anticonvulsant
  • Antiproliferative action
  • Genotoxicity assessment
  • Histamine H3 receptors
  • Maximal electroshock
  • Pentylenetetrazole
  • Strychnine

ASJC Scopus subject areas

  • Biochemistry
  • Toxicology
  • Pharmacology
  • Clinical Biochemistry
  • Biological Psychiatry
  • Behavioral Neuroscience


Dive into the research topics of 'Anticonvulsant evaluation of novel non-imidazole histamine H3R antagonists in different convulsion models in rats'. Together they form a unique fingerprint.

Cite this